- Active, Not enrolling
NCT02658929: Phase 1 - Study of bb2121 in BCMA-Expressing refractory Multiple Myeloma CRB-401
Updated: Sep 27, 2022
CRB-401
NCT02658929: Phase 1: Study of bb2121 in Multiple Myeloma
NCT02658929: Phase 1: Study of bb2121 in Multiple Myeloma
Study CRB-401 is a 2-part, non-randomized, open label, multi-site Phase 1 study of bb2121 in adults with relapsed/refractory multiple myeloma (MM). Experimental: bb2121 - bb2121 autologous CAR T cells will be infused at a dose ranging from 150 - 450 x 10^6 CAR+ T cells after receiving lymphodepleting chemotherapy.
This is a 2-part, non-randomized, open label, multi-site Phase 1 study. the study design consists of 2 parts: Part A (Dose Escalation), in which the RP2D is determined, and Part B (Expansion Cohorts), in which subjects are treated with the determined RP2D.
Sponsor
Collaborator
ClinicalTrials.gov Identifier: NCT02658929
Official Title: CRB-401 A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma
First Posted: January 20, 2016
Click here for details on ClinicalTrials.gov
CART - BCMA : National Cancer Institute
N Engl J Med : May 2nd, 2019
PMID: 31042825
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
CAR T-Cell Therapy in Multiple Myeloma Yields 100% Response Rate
Asco Post July, 2017
First-in-human multicenter study of bb2121 anti-BCMA CAR T-cell therapy for relapsed/refractory multiple myeloma: Updated results.
Meeting Abstract, ASCO 2017
- California: Stanford Cancer Center
- Massachusetts: Dana-Farber Cancer Institute/Harvard Cancer Center Boston
- Massachusetts: Massachusetts General Hospital Boston
- Minnesota: Mayo Clinic Rochester Minnesota
- New Jersey: Hackensack University Medical Center
- New York: Tisch Cancer Institute Mount Sinai Hospital New York
- Tennessee: Sarah Cannon Research Institute Nashville
Locations
United States, California
United States, Maryland
United States, Massachusetts
United States, Minnesota
United States, New Jersey
United States, New York
United States, Tennessee